- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04271956
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Barbara Eichhorst, Prof.
- Phone Number: +4922147888220
- Email: barbara.eichhorst@uk-koeln.de
Study Contact Backup
- Name: Othman Al-Sawaf, MD
- Phone Number: +4922147888220
- Email: othman.al-sawaf@uk-koeln.de
Study Locations
-
-
-
Vienna, Austria, 1090
- Allgemeines Krankenhaus Der Stadt Wien
-
-
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
-
-
-
Cologne, Germany, 50937
- Uniklinik Koln
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus
-
Essen, Germany, 45147
- Universitätsklinikum Essen
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein Campus Kiel
-
Landshut, Germany, 84036
- H.O.T Praxis Landshut
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg
-
Munich, Germany, 80804
- München Klinik Schwabing
-
Paderborn, Germany, 33098
- Brüderkrankenhaus St. Josef Paderborn
-
Rostock, Germany, 18057
- Universitatsmedizin Rostock
-
Ulm, Germany, 89081
- Universitätsklinik Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of CLL according to iwCLL criteria (Hallek et al, 2018)
- Confirmed histopathological diagnosis of RT
- Creatinine clearance ≥30ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured with 24hr urine collection
- Adequate liver function as indicated by a total bilirubin ≤ 2x, AST/ALT ≤ 2.5 x the institutional ULN value, unless directly attributable to the patient's CLL/RT or to Gilbert's Syndrome, in which case a max. total bilirubin ≤ 4 x and AST/ALT ≤ 5 x the institutional ULN value are required
- Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA PCR is performed every two months until 2 months after last dose of zanubrutinib), negative testing for hepatitis-C RNA and negative HIV test within 6 weeks prior to registration
- Age at least 18 years
- ECOG performance status 0-2, ECOG 3 is only permitted if related to CLL or RT (e.g. due to anaemia or severe constitutional symptoms)
- Life expectancy ≥ 6 months
- Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
- Patients who did not respond to previous line of RT therapy (i.e. primary progressive patients)
- Patients with more than one prior line of RT therapy
- Allogenic stem cell transplantation within the last 100 days or signs of active graft-versus-host disease (GVHD) after prior allogeneic stem cell transplantation within any time
- Patients with confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled autoimmune condition
- Malignancies other than CLL currently requiring systemic therapies
- Active infection currently requiring systemic treatment
- Any comorbidity or organ system impairment rated with a Cumulative Illness Rating Scale (CIRS) score of 4, excluding the eyes/ears/nose/throat/larynx organ system, or any other life-threatening illness, medical condition or organ system dysfunction that - in the investigator´s opinion could comprise the patients safety or interfere with the absorption or metabolism of the study drugs
- Requirement of therapy with strong CYP3A4 inhibitors/inducers
- Requirement of therapy with phenprocoumon or other vitamin K antagonists.
- Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs within clinical trials, which might interfere with the study drug within 28 days (or 5 times half-life [t1/2] of the compound, whichever is longer) prior to registration
- Known hypersensitivity to tislelizumab, zanubrutinib or any of the excipients
- Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment)
Fertile men or women of childbearing potential unless:
- surgically sterile or ≥ 2 years after the onset of menopause, or
- willing to use two methods of reliable contraception including one highly effective contraceptive method (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 12 months after the end of study treatment.
- Vaccination with a live vaccine <28 days prior to randomization
- Legal incapacity
- Prisoners or subjects who are institutionalized by regulatory or court order
- Persons who are in dependence to the sponsor or an investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tislelizumab + Zanubrutinib
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation |
Cycle (q21d): Day 1: Tislelizumab i.v.
200 mg
Other Names:
Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) after induction therapy according to the refined Lugano Classification (Cheson et al, 2016)
Time Frame: 18 weeks
|
Proportion of patients having achieved complete response (CR) or partial response (PR)
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR after induction therapy according to the IWCLL criteria (Hallek et al, 2018)
Time Frame: 18 weeks
|
Proportion of patients having achieved complete response (CR) or partial response (PR)
|
18 weeks
|
ORR after consolidation therapy
Time Frame: 36 weeks
|
Proportion of patients having achieved complete response (CR) or partial response (PR)
|
36 weeks
|
Progression-free Survival (PFS)
Time Frame: Up to 15 months
|
Time from the date of registration to the date of first occurrence of disease progression or relapse (determined according to the IWCLL guidelines and Lugano classification) or death from any cause, whichever occurs first
|
Up to 15 months
|
Overall Survival (OS)
Time Frame: Up to 15 months
|
Time from the date of registration to the date of death due to any cause
|
Up to 15 months
|
Time to Next Treatment (TTNT)
Time Frame: Up to 15 months
|
Time from date of registration to the date of first subsequent CLL/RT treatment
|
Up to 15 months
|
Duration of response
Time Frame: Up to 15 months
|
Time from the date of first documented response to the first occurrence of progression, relapse or death by any cause, whichever occurs first. Duration of response will be evaluated both according to the refined Lugano Classification as well as according to the IWCLL criteria. In the first case it will be calculated for patients with CR or PR, in the second case for patients with (clin.) CR, (clin.) CRi, PR, or PR-L. |
Up to 15 months
|
Type, frequency, severity of adverse events (AEs)
Time Frame: Up to 15 months
|
Up to 15 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Barbara Eichhorst, Prof., Department I of Internal Medicine, University Hospital Cologne
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLL-RT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Richter Transformation
-
Institute of Hematology & Blood Diseases HospitalXian-Janssen Pharmaceutical Ltd.Not yet recruitingRichter TransformationChina
-
German CLL Study GroupRecruitingCLL | Leukemia, Prolymphocytic, T-Cell | SLL | Leukemia, Prolymphocytic, B-Cell | HCL | T-LGL Leukemia | Richter´s Transformation | NK-LGL LeukemiaGermany
-
Niguarda HospitalRecruitingCLL TransformationItaly, Switzerland
-
Merck Sharp & Dohme LLCRecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation LymphomaPoland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
-
Acerta Pharma BVTerminatedDLBCL | Richter SyndromeUnited Kingdom, United States
-
French Innovative Leukemia OrganisationAmgenCompletedRichter SyndromeFrance
-
French Innovative Leukemia OrganisationHoffmann-La RocheRecruiting
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingRichter SyndromeUnited States
-
Northwell HealthPharmacyclics LLC.TerminatedRichter SyndromeUnited States
-
Central Hospital, Nancy, FranceInstitut National de la Santé Et de la Recherche Médicale, France; French Innovative...Recruiting
Clinical Trials on Tislelizumab
-
Peking University Cancer Hospital & InstituteRecruitingNon-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential ChemoradiationChina
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Henan Cancer HospitalNot yet recruiting
-
Shanghai Gopherwood Biotech Co., Ltd.RecruitingAdvanced Solid TumorChina
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
Fudan UniversityRecruitingRefractory Malignant AscitesChina
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
Peking UniversityRecruitingGastric Cancer | Colo-rectal CancerChina
-
Fudan UniversityNot yet recruiting